Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Congenital myopathies

INTRODUCTION

Congenital myopathies are a heterogenous group of primary muscle disorders that are present from birth, although their expression may be delayed until later in infancy or childhood. These conditions are rare. The most common are nemaline myopathy, central core disease, centronuclear/myotubular myopathies, and congenital fiber type disproportion (table 1).

OVERVIEW

Congenital myopathies share some common features, though severity is highly variable. Affected individuals usually present at birth or in infancy with hypotonia, weakness, hypoactive deep tendon reflexes, delayed motor milestones, and normal intelligence [1,2]. Prominent facial weakness and ptosis are often present; associated findings may include dysmorphic features such as dolichocephaly, a long, narrow face, and a high-arched palate. The weakness is usually generalized or more prominent in proximal and limb-girdle muscles. However, the weakness in some congenital myopathies predominantly affects distal muscles or axial and respiratory muscles. Muscle weakness tends to be stable or slowly progressive over time. In the most severe cases, the presentation is that of the floppy infant with a frog-leg posture and respiratory and bulbar weakness.

The specific congenital myopathies are characterized on the basis of their histologic and histochemical features. These conditions are caused by genetic abnormalities of muscle development. They are distinct from the metabolic myopathies, in which deficiencies of energy production in muscle result from defects in lipid metabolism, glycogenosis, or other metabolic pathways. (See "Causes of metabolic myopathies" and "Overview of inherited disorders of glucose and glycogen metabolism".)

No specific treatment is available for these disorders. Management consists of physical therapy, nutritional support, assisted ventilation if indicated, and genetic counseling.

NEMALINE MYOPATHY

Nemaline myopathy derives its name from the characteristic rod bodies in muscle that appear threadlike in longitudinal section.

                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Jun 19, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Romero NB, Clarke NF. Congenital myopathies. Handb Clin Neurol 2013; 113:1321.
  2. North KN. Clinical approach to the diagnosis of congenital myopathies. Semin Pediatr Neurol 2011; 18:216.
  3. Sarnat HB. New insights into the pathogenesis of congenital myopathies. J Child Neurol 1994; 9:193.
  4. Ryan MM, Schnell C, Strickland CD, et al. Nemaline myopathy: a clinical study of 143 cases. Ann Neurol 2001; 50:312.
  5. Wallgren-Pettersson C, Rapola J, Donner M. Pathology of congenital nemaline myopathy. A follow-up study. J Neurol Sci 1988; 83:243.
  6. Ishibashi-Ueda H, Imakita M, Yutani C, et al. Congenital nemaline myopathy with dilated cardiomyopathy: an autopsy study. Hum Pathol 1990; 21:77.
  7. Banwell BL, Singh NC, Ramsay DA. Prolonged survival in neonatal nemaline rod myopathy. Pediatr Neurol 1994; 10:335.
  8. Volpe JJ. Neuromuscular disorders: Muscle involvement and restricted disorders. In: Neurology of the Newborn, 5th ed, Saunders Elsevier, Philadelphia 2008. p.801.
  9. Wallgren-Pettersson C, Sainio K, Salmi T. Electromyography in congenital nemaline myopathy. Muscle Nerve 1989; 12:587.
  10. ENGEL WK, CUNNINGHAM GG. RAPID EXAMINATION OF MUSCLE TISSUE. AN IMPROVED TRICHROME METHOD FOR FRESH-FROZEN BIOPSY SECTIONS. Neurology 1963; 13:919.
  11. Gonatas NK. The fine structure of the rod-like bodies in nemaline myopathy and their relation to the Z-discs. J Neuropathol Exp Neurol 1966; 25:409.
  12. Regev R, de Vries LS, Heckmatt JZ, Dubowitz V. Cerebral ventricular dilation in congenital myotonic dystrophy. J Pediatr 1987; 111:372.
  13. Engel AG, Gomez MR. Nemaline (Z disk) myopathy: observations on the origin, structure, and solubility properties of the nemaline structures. J Neuropathol Exp Neurol 1967; 26:601.
  14. Sue CM, Hirano M, DiMauro S, De Vivo DC. Neonatal presentations of mitochondrial metabolic disorders. Semin Perinatol 1999; 23:113.
  15. Sanoudou D, Beggs AH. Clinical and genetic heterogeneity in nemaline myopathy--a disease of skeletal muscle thin filaments. Trends Mol Med 2001; 7:362.
  16. Nowak KJ, Wattanasirichaigoon D, Goebel HH, et al. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet 1999; 23:208.
  17. Johnston JJ, Kelley RI, Crawford TO, et al. A novel nemaline myopathy in the Amish caused by a mutation in troponin T1. Am J Hum Genet 2000; 67:814.
  18. Ilkovski B, Cooper ST, Nowak K, et al. Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene. Am J Hum Genet 2001; 68:1333.
  19. Gurgel-Giannetti J, Reed U, Bang ML, et al. Nebulin expression in patients with nemaline myopathy. Neuromuscul Disord 2001; 11:154.
  20. Donner K, Ollikainen M, Ridanpää M, et al. Mutations in the beta-tropomyosin (TPM2) gene--a rare cause of nemaline myopathy. Neuromuscul Disord 2002; 12:151.
  21. Corbett MA, Akkari PA, Domazetovska A, et al. An alphaTropomyosin mutation alters dimer preference in nemaline myopathy. Ann Neurol 2005; 57:42.
  22. Agrawal PB, Greenleaf RS, Tomczak KK, et al. Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2. Am J Hum Genet 2007; 80:162.
  23. Agrawal PB, Strickland CD, Midgett C, et al. Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations. Ann Neurol 2004; 56:86.
  24. Wallgren-Pettersson C, Pelin K, Hilpelä P, et al. Clinical and genetic heterogeneity in autosomal recessive nemaline myopathy. Neuromuscul Disord 1999; 9:564.
  25. Olivé M, Goldfarb LG, Lee HS, et al. Nemaline myopathy type 6: clinical and myopathological features. Muscle Nerve 2010; 42:901.
  26. Gommans IM, Davis M, Saar K, et al. A locus on chromosome 15q for a dominantly inherited nemaline myopathy with core-like lesions. Brain 2003; 126:1545.
  27. Sambuughin N, Yau KS, Olivé M, et al. Dominant mutations in KBTBD13, a member of the BTB/Kelch family, cause nemaline myopathy with cores. Am J Hum Genet 2010; 87:842.
  28. Shuaib A, Paasuke RT, Brownell KW. Central core disease. Clinical features in 13 patients. Medicine (Baltimore) 1987; 66:389.
  29. Quinlivan RM, Muller CR, Davis M, et al. Central core disease: clinical, pathological, and genetic features. Arch Dis Child 2003; 88:1051.
  30. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15:410.
  31. Lamont PJ, Dubowitz V, Landon DN, et al. Fifty year follow-up of a patient with central core disease shows slow but definite progression. Neuromuscul Disord 1998; 8:385.
  32. Akiyama C, Nonaka I. A follow-up study of congenital non-progressive myopathies. Brain Dev 1996; 18:404.
  33. Imoto C, Nonaka I. The significance of type 1 fiber atrophy (hypotrophy) in childhood neuromuscular disorders. Brain Dev 2001; 23:298.
  34. Wu S, Ibarra MC, Malicdan MC, et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006; 129:1470.
  35. Kossugue PM, Paim JF, Navarro MM, et al. Central core disease due to recessive mutations in RYR1 gene: is it more common than described? Muscle Nerve 2007; 35:670.
  36. Bharucha-Goebel DX, Santi M, Medne L, et al. Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrum. Neurology 2013; 80:1584.
  37. Avila G, O'Brien JJ, Dirksen RT. Excitation--contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proc Natl Acad Sci U S A 2001; 98:4215.
  38. Jungbluth H. Multi-minicore Disease. Orphanet J Rare Dis 2007; 2:31.
  39. Beggs AH, Agrawal PB. Multiminicore Disease. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1290/ (Accessed on March 22, 2011).
  40. Ferreiro A, Estournet B, Chateau D, et al. Multi-minicore disease--searching for boundaries: phenotype analysis of 38 cases. Ann Neurol 2000; 48:745.
  41. Willemsen MA, van Oort AM, ter Laak HJ, et al. Multicore myopathy with restrictive cardiomyopathy. Acta Paediatr 1997; 86:1271.
  42. Ferreiro A, Quijano-Roy S, Pichereau C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002; 71:739.
  43. Dubowitz V. Rigid spine syndrome: a muscle syndrome in search of a name. Proc R Soc Med 1973; 66:219.
  44. Moghadaszadeh B, Desguerre I, Topaloglu H, et al. Identification of a new locus for a peculiar form of congenital muscular dystrophy with early rigidity of the spine, on chromosome 1p35-36. Am J Hum Genet 1998; 62:1439.
  45. Moghadaszadeh B, Petit N, Jaillard C, et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat Genet 2001; 29:17.
  46. Scoto M, Cirak S, Mein R, et al. SEPN1-related myopathies: clinical course in a large cohort of patients. Neurology 2011; 76:2073.
  47. Ferreiro A, Monnier N, Romero NB, et al. A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. Ann Neurol 2002; 51:750.
  48. Monnier N, Ferreiro A, Marty I, et al. A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia. Hum Mol Genet 2003; 12:1171.
  49. Jungbluth H, Zhou H, Hartley L, et al. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology 2005; 65:1930.
  50. Bartsch O, Kress W, Wagner A, Seemanova E. The novel contiguous gene syndrome of myotubular myopathy (MTM1), male hypogenitalism and deletion in Xq28:report of the first familial case. Cytogenet Cell Genet 1999; 85:310.
  51. Sutton IJ, Winer JB, Norman AN, et al. Limb girdle and facial weakness in female carriers of X-linked myotubular myopathy mutations. Neurology 2001; 57:900.
  52. Herman GE, Finegold M, Zhao W, et al. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr 1999; 134:206.
  53. Jeannet PY, Bassez G, Eymard B, et al. Clinical and histologic findings in autosomal centronuclear myopathy. Neurology 2004; 62:1484.
  54. Sarnat HB. Cerebral dysgeneses and their influence on fetal muscle development. Brain Dev 1986; 8:495.
  55. Fidziańska A, Warlo I, Goebel HH. Neonatal centronuclear myopathy with N-CAM decorated myotubes. Neuropediatrics 1994; 25:158.
  56. Mora M, Morandi L, Merlini L, et al. Fetus-like dystrophin expression and other cytoskeletal protein abnormalities in centronuclear myopathies. Muscle Nerve 1994; 17:1176.
  57. De Angelis MS, Palmucci L, Leone M, Doriguzzi C. Centronuclear myopathy: clinical, morphological and genetic characters. A review of 288 cases. J Neurol Sci 1991; 103:2.
  58. Darras BT. Neuromuscular disorders in the newborn. Clin Perinatol 1997; 24:827.
  59. Bitoun M, Maugenre S, Jeannet PY, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 2005; 37:1207.
  60. Bitoun M, Bevilacqua JA, Prudhon B, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 2007; 62:666.
  61. Blondeau F, Laporte J, Bodin S, et al. Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum Mol Genet 2000; 9:2223.
  62. Taylor GS, Maehama T, Dixon JE. Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Proc Natl Acad Sci U S A 2000; 97:8910.
  63. Liechti-Gallati S, Müller B, Grimm T, et al. X-linked centronuclear myopathy: mapping the gene to Xq28. Neuromuscul Disord 1991; 1:239.
  64. Laporte J, Kress W, Mandel JL. Diagnosis of X-linked myotubular myopathy by detection of myotubularin. Ann Neurol 2001; 50:42.
  65. D'Amico A, Bertini E. Congenital myopathies. Curr Neurol Neurosci Rep 2008; 8:73.
  66. Laporte J, Biancalana V, Tanner SM, et al. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat 2000; 15:393.
  67. Tanner SM, Laporte J, Guiraud-Chaumeil C, Liechti-Gallati S. Confirmation of prenatal diagnosis results of X-linked recessive myotubular myopathy by mutational screening, and description of three new mutations in the MTM1 gene. Hum Mutat 1998; 11:62.
  68. Wilmshurst JM, Lillis S, Zhou H, et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 2010; 68:717.
  69. Nicot AS, Toussaint A, Tosch V, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 2007; 39:1134.
  70. Ceyhan-Birsoy O, Agrawal PB, Hidalgo C, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology 2013; 81:1205.
  71. Bigner DR, Rijhsinghani A, Yankowitz J. Congenital fiber-type disproportion presenting antenatally with clubfoot and hydramnios. Gynecol Obstet Invest 2000; 49:275.
  72. Tsuji M, Higuchi Y, Shiraishi K, et al. Congenital fiber type disproportion: severe form with marked improvement. Pediatr Neurol 1999; 21:658.
  73. Bartholomeus MG, Gabreëls FJ, ter Laak HJ, van Engelen BG. Congenital fibre type disproportion a time-locked diagnosis: a clinical and morphological follow-up study. Clin Neurol Neurosurg 2000; 102:97.
  74. Sobrido MJ, Fernández JM, Fontoira E, et al. Autosomal dominant congenital fibre type disproportion: a clinicopathological and imaging study of a large family. Brain 2005; 128:1716.
  75. Mizuno Y, Komiya K. A serial muscle biopsy study in a case of congenital fiber-type disproportion associated with progressive respiratory failure. Brain Dev 1990; 12:431.
  76. Banwell BL, Becker LE, Jay V, et al. Cardiac manifestations of congenital fiber-type disproportion myopathy. J Child Neurol 1999; 14:83.
  77. Clarke NF, Kolski H, Dye DE, et al. Mutations in TPM3 are a common cause of congenital fiber type disproportion. Ann Neurol 2008; 63:329.
  78. Laing NG, Clarke NF, Dye DE, et al. Actin mutations are one cause of congenital fibre type disproportion. Ann Neurol 2004; 56:689.
  79. Clarke NF, Kidson W, Quijano-Roy S, et al. SEPN1: associated with congenital fiber-type disproportion and insulin resistance. Ann Neurol 2006; 59:546.
  80. Clarke NF, Waddell LB, Cooper ST, et al. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Hum Mutat 2010; 31:E1544.
  81. DeChene ET, Kang PB, Beggs AH. Congenital fiber-type disproportion. www.ncbi.nlm.nih.gov/books/NBK1259/ (Accessed on March 22, 2011).
  82. Clarke NF, Smith RL, Bahlo M, North KN. A novel X-linked form of congenital fiber-type disproportion. Ann Neurol 2005; 58:767.
  83. Clarke NF, Ilkovski B, Cooper S, et al. The pathogenesis of ACTA1-related congenital fiber type disproportion. Ann Neurol 2007; 61:552.
  84. Laing NG. Congenital myopathies. Curr Opin Neurol 2007; 20:583.
  85. Sewry CA, Jimenez-Mallebrera C, Muntoni F. Congenital myopathies. Curr Opin Neurol 2008; 21:569.
  86. Logan CV, Lucke B, Pottinger C, et al. Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD). Nat Genet 2011; 43:1189.
  87. Hartley L, Kinali M, Knight R, et al. A congenital myopathy with diaphragmatic weakness not linked to the SMARD1 locus. Neuromuscul Disord 2007; 17:174.